<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462330</url>
  </required_header>
  <id_info>
    <org_study_id>10 142 01</org_study_id>
    <nct_id>NCT02462330</nct_id>
  </id_info>
  <brief_title>Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)</brief_title>
  <acronym>MESAMI2</acronym>
  <official_title>Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cell therapy is an emerging treatment for cardiovascular disease but the best cell type&#xD;
      and delivery method remain to be determined. Pre-clinical studies demonstrated improvement of&#xD;
      cardiac function by Mesenchymal stem cells (MSC) therapy in particular by their paracrine and&#xD;
      immunosuppressive properties. Investigators initiated the MESAMI program by the bicentric&#xD;
      pilot phase and highlighted the safety and feasibility of intramyocardial injections of MSCs&#xD;
      from bone marrow in patients with chronic ischemic cardiomyopathy and left ventricular&#xD;
      dysfunction, guide by the NOGA-XP system. The MESAMI program continues with the phase 2,&#xD;
      multicenter, double-blind, randomized, placebo-controlled trial.The aim of this phase 2 study&#xD;
      is to demonstrate a functional improvement, measuring peak VO2, at 3 months between the cell&#xD;
      therapy group and the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic cardiomyopathies are a leading cause of death in both men and women. During the last&#xD;
      decade, treatments for heart failure have evolved, but their purpose is to improve symptoms&#xD;
      and prevent aggravation of the disease. Current research is focusing on the development of&#xD;
      cell-based therapies using different sources of stem cells which can provide trophic and&#xD;
      paracrine support or even replace dying cells with new ones. A specific form of stem cells,&#xD;
      called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. These cells&#xD;
      are known for their ability to secrete paracrine factors and their immunosuppressive&#xD;
      properties. The MESAMI 2 study will evaluate the efficacy of MSCs injection directly into the&#xD;
      heart to repair and restore heart function in people with chronic ischemic heart failure&#xD;
      using NOGA-XP system.&#xD;
&#xD;
      This phase 2 study is a prospective, multicenter, double-blind, randomized,&#xD;
      placebo-controlled trial. A total of 90 patients will be randomized in 2 arms to receive&#xD;
      intramyocardial injection of MSCs or placebo. Patients will be followed up for 13 months.&#xD;
      Bone marrow will be collected and immediately transported to the French Blood Establishment&#xD;
      for MSC isolation and expansion. Patients will receive intramyocardial injection of MSCs or&#xD;
      placebo during a left heart catheterization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VO2max</measure>
    <time_frame>3 months</time_frame>
    <description>Change in VO2max (or peak VO2) before injection and at 3 months post injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular viability</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA/CCS class</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change on class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Minnesota questionnaire)</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change on quality of life test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>At 6 and 12 months</time_frame>
    <description>Change in VO2max (or peak VO2) at 6 and 12 months post injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6'walking-test</measure>
    <time_frame>Between 3 and 12 months</time_frame>
    <description>Distance to walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Volume of myocardium and measurement of ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion imaging</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Efficacy of the cell therapy on LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP blood test</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change of the BNP blood test at 3, 6 and 12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event related to cell administration</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Complication related to cell administration</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Control of the implantable cardioverter defibrillator</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of major cardiovascular events</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection of human albumin 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous MSC from bone marrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramyocardial injection of 6.10e7 stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous MSC from bone marrow</intervention_name>
    <description>After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.</description>
    <arm_group_label>Autologous MSC from bone marrow</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>injections of human albumin</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Human Albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who signed the informed consent,&#xD;
&#xD;
          -  Chronic stable ischemic cardiomyopathy for at least one month with a NYHA Class II-IV&#xD;
             and/or -Angina pectoris CCS Class III or IV,&#xD;
&#xD;
          -  Not a candidate for revascularization by coronary artery by-pass surgery or&#xD;
             angioplasty,&#xD;
&#xD;
          -  Left ventricular function ≤45%,&#xD;
&#xD;
          -  Presence of ischemia or myocardial viability on the myocardial perfusion imaging,&#xD;
&#xD;
          -  VO2 max≤ 20 ml/min/kg,&#xD;
&#xD;
          -  Optimal medical therapy,&#xD;
&#xD;
          -  Optimal interventional therapy (Implantable Cardiovertor Defibrillator, effort&#xD;
             rehabilitation).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding,&#xD;
&#xD;
          -  Acute coronary syndrome or myocardial infarction during the last 3 months,&#xD;
&#xD;
          -  Revascularization (PCI or CABG), or cardiac resynchronization during the last 3&#xD;
             months,&#xD;
&#xD;
          -  Further revascularization planned for the next 30 days,&#xD;
&#xD;
          -  LVEF &gt;45%,&#xD;
&#xD;
          -  Left intraventricular Thrombus and / or ventricular aneurysm detected by transthoracic&#xD;
             echocardiography,&#xD;
&#xD;
          -  Wall thickness in the target region &lt;8 mm as determined by echocardiography,&#xD;
&#xD;
          -  Critical Limb Ischemia stages 3 or 4,&#xD;
&#xD;
          -  Inability to achieve a VO2 test,&#xD;
&#xD;
          -  Not feasible peripheral arterial access for percutaneous procedure,&#xD;
&#xD;
          -  Aortic stenosis (&lt;1cm²) or aortic insufficiency (&gt; 2 +),&#xD;
&#xD;
          -  Patients with transplanted organ,&#xD;
&#xD;
          -  Chronic renal failure with creatinemia ≥ 250 µmol/L,&#xD;
&#xD;
          -  Severe hepatic dysfunction,&#xD;
&#xD;
          -  Chronic atrial fibrillation,&#xD;
&#xD;
          -  Decompensated heart failure,&#xD;
&#xD;
          -  Uncontrolled Ventricular arrhythmias,&#xD;
&#xD;
          -  Indication of cardiac resynchronization by multisite pacemaker or cardiac&#xD;
             resynchronization during the last 3 months,&#xD;
&#xD;
          -  Obesity preventing bone marrow aspiration or manual compression of the puncture area&#xD;
             after bone marrow collection,&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Immuno-modulator treatment (ciclosporin, mycophenolate, mycophenolate mofetil,&#xD;
             azathioprine, tacrolimus, anthracyclines, neupogen, hydrea, etanercept interferons,&#xD;
             prednisolone, methylprednisolone, colchicine),&#xD;
&#xD;
          -  History of cancer in the last 5 years,&#xD;
&#xD;
          -  Hemopathy, hematopoietic disease,&#xD;
&#xD;
          -  Haemorrhagic syndrome,&#xD;
&#xD;
          -  Chronic or progressive disease that may alter the prognosis within 3 months,&#xD;
&#xD;
          -  Positive serologies for Human immunodeficiency virus (HIV1-2), HTLV-1 (human T-cell&#xD;
             lymphotrophic virus) and 2, HBV (hepatitis B virus) or HCV (hepatitis B virus).&#xD;
&#xD;
          -  Allergic to xylocain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerôme Roncalli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerôme Roncalli, MD, PhD</last_name>
    <phone>05 61 32 26 13</phone>
    <phone_ext>+33</phone_ext>
    <email>roncalli.j@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine Pauze</last_name>
    <phone>05 61 77 84 34</phone>
    <email>pauze.a@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Teiger, MD, PhD</last_name>
      <phone>01 49 81 21 11</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuel.teiger@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Teiger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yannick Neuder</last_name>
      <phone>04 76 76 84 66</phone>
      <phone_ext>+33</phone_ext>
      <email>YNeuder@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick Neuder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Van Belle, MD, PhD</last_name>
      <phone>03 20 44 59 62</phone>
      <phone_ext>+33</phone_ext>
      <email>ericvanbelle@aol.com</email>
    </contact>
    <investigator>
      <last_name>Eric Van Belle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Noël Trochu, MD, PhD</last_name>
      <phone>02 40 16 52 77</phone>
      <phone_ext>+33</phone_ext>
      <email>jeannoel.trochu@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Noël Trochu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Isnard, MD, PhD</last_name>
      <phone>01 42 16 30 09</phone>
      <phone_ext>+33</phone_ext>
      <email>richard.isnard@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Richard Isnard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Department of Rangueil Hospital - Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerôme Roncalli, MD, PhD</last_name>
      <phone>05 61 32 26 13</phone>
      <phone_ext>+33</phone_ext>
      <email>roncalli.j@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marine Lebrin</last_name>
      <phone>05 61 32 37 24</phone>
      <phone_ext>+33</phone_ext>
      <email>lebrin.m@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jerôme Roncalli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>ischemic cardiomyopathy</keyword>
  <keyword>NogaStar XP system catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

